Vous êtes ici : Accueil > Labo BCI > -- Équipe BAL > Publications de l'équipe BAL

Publications de l'équipe BAL

Publié le 12 septembre 2018


2018 


Ferreira RR, Madeira FD, Alves GF, Chambela MD, Curvo EDV, Moreira AD, de Sa RA, Mendonca-Lima L, Cabello PH, Bailly S, Feige JJ, Araujo-Jorge TC, Saraiva RM and Waghabi MC
TGF-ß polymorphisms are a risk factor for chagas disease.
Disease Markers, 2018: Article Number 4579198

Goumans MJ, Zwijsen A, Ten Dijke P and Bailly S
Bone morphogenetic proteins in vascular homeostasis and disease.
Cold Spring Harbor Perspectives in Biology, 2018, 10(2): a031989

Ouarné M, Bouvard C, Boneva G, Mallet C, Ribeiro J, Desroches-Castan A, Soleilhac E, Tillet E, Peyruchaud O and Bailly S
BMP9, but not BMP10, acts as a quiescence factor on tumor growth, vessel normalization and metastasis in a mouse model of breast cancer.
Journal of Experimental & Clinical Cancer Research, 2018, 37(1): 209

Tillet E, Ouarné M, Desroches-Castan A, Mallet C, Subileau M, Didier R, Lioutsko A, Belthier G, Feige JJ and Bailly S
A heterodimer formed by bone morphogenetic protein 9 (BMP9) and BMP10 provides most BMP biological activity in plasma.
Journal of Biological Chemistry, 2018


2017 


Arvin-Berod M, Desroches-Castan A, Bonte S, Brugière S, Couté Y, Guyon L, Feige JJ, Baussanne I and Demeunynck M
Indolizine-based scaffolds as efficient and versatile tools: Application to the synthesis of biotin-tagged antiangiogenic drugs.
ACS Omega, 2017, 2(12): 9221-9230

Goumans MJ, Zwijsen A, ten Dijke P and Bailly S
BMPs in vascular homeostasis and disease.
Cold Spring Harbor Perspectives in Biology, 2017

Guignabert C, Bailly S and Humbert M
Restoring BMPRII functions in pulmonary arterial hypertension: Opportunities, challenges and limitations.
Expert Opinion on Therapeutic Targets, 2017, 21(2): 181-190


2016 

Ferreira RR, de Souza EM, de Oliveira FL, Ferrao PM, Gomes LH, Mendonca-Lima L, Meuser-Batista M, Bailly S, Feige JJ, de Araujo-Jorge TC and Waghabi MC
Proteins involved on TGF-ß pathway are up-regulated during the acute phase of experimental Chagas disease.
Immunobiology, 2016, 221(5): 587-594

García de Vinuesa A, Abdelilah-Seyfried S, Knaus P, Zwijsen A and Bailly S
BMP signaling in vascular biology and dysfunction.
Cytokine Growth Factor Reviews, 2016, 27: 65-79


2015 


el Din FA, Patri S, Thoreau V, Rodriguez-Ballesteros M, Hamade E, Bailly S, Gilbert-Dussardier B, Abou Merhi R and Kitzis A
Functional and splicing defect analysis of 23 ACVRL1 mutations in a cohort of patients affected by hereditary hemorrhagic telangiectasia.
PLoS One, 2015, 10(7): e0132111

Ferrão PM, d'Avila-Levy CM, Araujo-Jorge TC, Degrave WM, Goncalves AD, Garzoni LR, Lima AP, Feige JJ, Bailly S, Mendonça-Lima L and Waghabi MC
Cruzipain activates latent TGF-ß from host cells during T. cruzi invasion.
PLoS One, 2015, 10(5): e0124832

Levet S, Ouarne M, Ciais D, Coutton C, Subileau M, Mallet C, Ricard N, Bidart M, Debillon T, Faravelli F, Rooryck C, Feige JJ, Tillet E and Bailly S
BMP9 and BMP10 are necessary for proper closure of the ductus arteriosus.
Proceedings of the National Academy of Sciences, 2015, 112(25): E3207-3215

Mallet C, Lamribet K, Giraud S, Dupuis-Girod S, Feige JJ, Bailly S and Tillet E
Functional analysis of endoglin mutations from hereditary hemorrhagic telangiectasia type 1 patients reveals different mechanisms for endoglin loss of function.
Human Molecular Genetics, 2015, 24(1): 1142-1154

Tillet E and Bailly S
Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Frontiers in Genetics, 2015, 5: n°456


2014 


Bailly S
BMP9, BMP10 and ALK1: An emerging vascular signalling pathway with therapeutic applications. In Molecular mechanisms of angiogenesis: From ontogenesis to oncogenesis. Feige J.J., Pagès G. & Soncin F. Eds, Springer, 2014, pp 99-119

Levet S, Ricard N, Ciais D, Subileau M, Mallet C, Feige JJ, Vittet D and Bailly S
Specificity and redundancy of BMP9 and BMP10 in postnatal angiogenesis and lymphangiogenesis.
Angiogenesis, 2014, 17(1): 293-294

Tillet E and Bailly S
Emerging roles of BMP9 and BMP10 in hereditary hemorrhagic telangiectasia.
Frontiers in Genetics, 2014, 5: n°456

Vittet D
Lymphatic collecting vessel maturation and valve morphogenesis.
Microvascular Research, 2014
, 96: 31-37


Vittet D, Brouillet S, Hoffmann P, Alfaidy N and Feige JJ
Cultures de cellules endothéliales. Applications à l’étude de l’angiogenèse In Culture de cellules animales, edited by Barlovatz-Meimon G and Ronot X, Editions Inserm, 2014


2013 


Levet S, Ciais D, Merdzhanova G, Mallet C, Zimmers TA, Lee SJ, Navarro FP, Texier I, Feige JJ, Bailly S and Vittet D
Bone morphogenetic protein 9 (BMP9) controls lymphatic vessel maturation and valve formation.
Blood, 2013, 122(4): 598-607


2012 


Araujo-Jorge TC, Waghabi MC, Bailly S and Feige JJ
The TGF-beta pathway as an emerging target for Chagas disease therapy.
Clinical Pharmacology & Therapeutics, 2012, 92(5): 613-621

Bidart M, Ricard N, Levet S, Samson M, Mallet C, David L, Subileau M, Tillet E, Feige JJ and Bailly S
BMP9 is produced by hepatocytes and circulates mainly in an active mature form complexed to its prodomain.
Cellular and Molecular Life Sciences, 2012, 69(2): 313-324
Erratum in: Cell Mol Life Sci, 2012, 69(3):485

Ciais D and Bailly S
BMPs go for apelin to regulate angiogenesis. Focus on "Inhibition of apelin expression by BMP signaling in endothelial cells".
American Journal of Physiology-Cell Physiology, 2012, 303(11): C1127-1128

Dupuis-Girod S, Ginon I, Saurin JC, Marion D, Guillot E, Decullier E, Roux A, Carette MF, Gilbert-Dussardier B, Hatron PY, Lacombe P, Lorcerie B, Rivière S, Corre R, Giraud S, Bailly S, Paintaud G, Ternant D, Valette PJ, Plauchu H and Faure F
Bevacizumab in patients with hereditary hemorrhagic telangiectasia and severe hepatic vascular malformations and high cardiac output.
Journal of the American Medical Association, 2012, 307(9): 948-955

Liu F, Kang I, Park C, Chang LW, Wang W, Lee D, Lim DS, Vittet D, Nerbonne JM and Choi K
ER71 specifies Flk-1+ hemangiogenic mesoderm by inhibiting cardiac mesoderm and Wnt signaling.
Blood, 2012, 119(14): 3295-3305

de Oliveira FL, Araujo-Jorge TC, de Souza EM, de Oliveira GM, Degrave WM, Feige JJ, Bailly S and Waghabi MC
Oral administration of GW788388, an inhibitor of transforming growth factor beta signaling, prevents heart fibrosis in chagas disease.
PLoS Neglected Tropical Diseases, 2012, 6(6): e1696

Ricard N, Ciais D, Levet S, Subileau M, Mallet C, Zimmers TA, Lee SJ, Bidart M, Feige JJ and Bailly S
BMP9 and BMP10 are critical for postnatal retinal vascular remodeling.
Blood, 2012, 119(25): 6162-6171

Vittet D, Merdzhanova G, Prandini MH, Feige JJ and Bailly S
TGFss1 inhibits lymphatic endothelial cell differentiation from mouse embryonic stem cells.
Journal of Cellular Physiology, 2012, 227(11): 3593-3602


2010 


Bailly S, Dupuis-Girod S and Plauchu H
Rendu-Osler disease: Clinical and molecular update.
Médecine Sciences (Paris), 2010, 26(10): 855-860

Dupuis-Girod S, Bailly S and Plauchu H
Hereditary hemorrhagic telangiectasia (HHT): From molecular biology to patient care.
Journal of Thrombosis and Haemostasis, 2010, 8(7): 1447-1456

Ricard N, Bidart M, Mallet C, Lesca G, Giraud S, Prudent R, Feige JJ and Bailly S
Functional analysis of the BMP9 response of ALK1 mutants from HHT2 patients: a diagnostic tool for novel ACVRL1 mutations.
Blood, 2010, 116(9): 1604-1612


2009 


David L, Feige JJ and Bailly S
Emerging role of bone morphogenetic proteins in angiogenesis.
Cytokine Growth Factor Reviews, 2009, 20(3): 203-212

Waghabi MC, de Souza EM, de Oliveira GM, Keramidas M, Feige JJ, Araújo-Jorge TC and Bailly S
Pharmacological inhibition of transforming growth factor beta signalling decreases infection and prevents heart damage in acute chagas disease.
Antimicrobial Agents Chemotherapy, 2009, 53(11): 4694-4701


2008 


Araujo-Jorge TC, Waghabi MC, Soeiro MD, Keramidas M, Bailly S and Feige JJ
Pivotal role for TGF-ß in infectious heart disease: The case of Trypanosoma cruzi infection and consequent Chagasic myocardiopathy.
Cytokine and Growth Factor Reviews, 2008, 19(5-6): 405-413

Bailly S
HHT is not a TGFß disease.
Blood, 2008, 111(2); 478

David L, Mallet C, Keramidas M, Lamandé N, Gasc JM, Dupuis-Girod S, Plauchu H, Feige JJ and Bailly S
Bone morphogenetic protein-9 is a circulating vascular quiescence factor.
Circulation Research, 2008, 102(8): 914-922


2007 


David L, Mallet C, Mazerbourg S, Feige JJ and Bailly S
Identification of BMP9 and BMP10 as functional activators of the orphan activin receptor-like kinase 1 (ALK1) in endothelial cells.
Blood, 2007, 109(5): 1953-1961

David L, Mallet C, Vailhe B, Lamouille S, Feige JJ and Bailly S
Activin receptor-like kinase 1 inhibits human microvascular endothelial cell migration: Potential roles for JNK and ERK.
Journal of Cellular Physiology, 2007, 213(2): 484-489

Vittet D and Feige JJ
Lymphangiogenesis and tumor progression.
Bulletin du Cancer, 2007, 94(10): 881-886

Waghabi MC, Keramidas M, Calvet CM, Meuser M, Soeiro MD, Mendonca-Lima L, Araujo-Jorge TC, Feige JJ and Bailly S
SB-431542, a transforming growth factor ß inhibitor, impairs Trypannosoma cruzi infection in cardiomyocytes and parasite cycle completion.
Antimicrobial Agents and Chemotheraphy, 2007, 51(8): 2905-2910


2006 


Mallet C, Vittet D, Feige JJ and Bailly S
TGFß1 induces vasculogenesis and inhibits angiogenic sprouting in an embryonic stem cell differentiation model: Respective contribution of ALK1 and ALK5.
Stem Cells, 2006, 24(11): 2420-2427